Cannabichromene

Cannabichromene (CBC) is a non-psychoactive phytocannabinoid found in Cannabis sativa. It is typically present at lower concentrations than CBD or THC, though its levels vary considerably among strains and growing conditions. In cannabis plants, CBC exists primarily as cannabichromenic acid (CBCA); enzymatic conversion of cannabigerolic acid (CBGA) by CBC synthase yields CBCA, which decarboxylates to CBC during drying or heating.

Pharmacology and effects

CBC binds weakly to CB1 and CB2 receptors and does not cause intoxication. It is thought to influence endocannabinoid signaling indirectly, including inhibition of anandamide reuptake, which can prolong endocannabinoid activity. CBC also interacts with several non-endocannabinoid targets, particularly transient receptor potential channels such as TRPV1 and TRPA1, which are implicated in pain sensation and inflammation. Preclinical studies have reported anti-inflammatory, analgesic, antimicrobial, antifungal, and potential anti-tumor effects, though evidence is limited and mechanisms are not fully understood. CBC is often studied in combination with other cannabinoids as part of the entourage effect.

Research status and safety

Much of the evidence comes from cell culture and animal studies; robust clinical data in humans are sparse. CBC is generally considered non-psychoactive, but the safety data are limited. As with other cannabis constituents, potential interactions with other medications are not well defined.